A Phase 1, Open-label, Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 06 Dec 2017 Planned End Date changed from 29 Apr 2020 to 30 Apr 2020.
- 09 Nov 2017 Planned End Date changed from 31 Oct 2020 to 29 Apr 2020.
- 09 Jun 2017 Planned number of patients changed from 20 to 50.